Von Willebrand factor: a possible biomarker for disease activity in vasculitis.

IF 2.2 4区 医学 Q3 RHEUMATOLOGY
Scandinavian Journal of Rheumatology Pub Date : 2024-11-01 Epub Date: 2024-02-05 DOI:10.1080/03009742.2024.2302679
S Keret, J Mazareeb, A Snir, A Shouval, A Awisat, L Kaly, I Rosner, M Rozenbaum, N Boulman, E Hardak, G Slobodin, D Rimar
{"title":"Von Willebrand factor: a possible biomarker for disease activity in vasculitis.","authors":"S Keret, J Mazareeb, A Snir, A Shouval, A Awisat, L Kaly, I Rosner, M Rozenbaum, N Boulman, E Hardak, G Slobodin, D Rimar","doi":"10.1080/03009742.2024.2302679","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Inflammation markers, e.g. C- reactive protein (CRP) and sedimentation rate, can be normal despite active vasculitis. Von Willebrand factor (vWF) is secreted from endothelial cells in response to vascular damage. Some reports suggest increased vWF levels in vasculitis. This study aimed to evaluate vWF serum concentration in vasculitis patients as a possible biomarker of disease activity and to review the current literature.</p><p><strong>Method: </strong>Adult patients with systemic vasculitis were prospectively enrolled. Disease activity was recorded using the Birmingham Vasculitis Activity Score (BVAS) version 3. Blood group-adjusted vWF antigen serum level was evaluated at diagnosis and, when available, after treatment.</p><p><strong>Results: </strong>Twenty-five vasculitis patients were compared to 15 healthy controls. The mean age of patients was 56 ± 17 years and 56% were women. Forty percent had anti-neutrophil cytoplasmic autoantibody-associated vasculitis, 20% giant cell arteritis, 16% polyarteritis nodosa, 8% Takayasu arteritis, and the rest had other vasculitides. The mean disease duration was 3.4 ± 4.8 years. Mean vWF was higher in patients with active vasculitis than in healthy controls (212 ± 81% vs 106 ± 26%, p < 0.001). vWF levels directly correlated with BVAS. In 13 patients with active vasculitis who reached remission or low disease activity after treatment, vWF level at follow-up decreased significantly. In three out of five patients who were treated with interleukin-6 inhibitors, vWF was elevated despite normal CRP levels, while vasculitis was clinically active.</p><p><strong>Conclusion: </strong>vWF antigen serum level is increased in active vasculitis and could potentially serve as a biomarker for active disease.</p>","PeriodicalId":21424,"journal":{"name":"Scandinavian Journal of Rheumatology","volume":" ","pages":"433-441"},"PeriodicalIF":2.2000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Scandinavian Journal of Rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/03009742.2024.2302679","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/5 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: Inflammation markers, e.g. C- reactive protein (CRP) and sedimentation rate, can be normal despite active vasculitis. Von Willebrand factor (vWF) is secreted from endothelial cells in response to vascular damage. Some reports suggest increased vWF levels in vasculitis. This study aimed to evaluate vWF serum concentration in vasculitis patients as a possible biomarker of disease activity and to review the current literature.

Method: Adult patients with systemic vasculitis were prospectively enrolled. Disease activity was recorded using the Birmingham Vasculitis Activity Score (BVAS) version 3. Blood group-adjusted vWF antigen serum level was evaluated at diagnosis and, when available, after treatment.

Results: Twenty-five vasculitis patients were compared to 15 healthy controls. The mean age of patients was 56 ± 17 years and 56% were women. Forty percent had anti-neutrophil cytoplasmic autoantibody-associated vasculitis, 20% giant cell arteritis, 16% polyarteritis nodosa, 8% Takayasu arteritis, and the rest had other vasculitides. The mean disease duration was 3.4 ± 4.8 years. Mean vWF was higher in patients with active vasculitis than in healthy controls (212 ± 81% vs 106 ± 26%, p < 0.001). vWF levels directly correlated with BVAS. In 13 patients with active vasculitis who reached remission or low disease activity after treatment, vWF level at follow-up decreased significantly. In three out of five patients who were treated with interleukin-6 inhibitors, vWF was elevated despite normal CRP levels, while vasculitis was clinically active.

Conclusion: vWF antigen serum level is increased in active vasculitis and could potentially serve as a biomarker for active disease.

冯-威廉因子:脉管炎疾病活动的可能生物标志物。
目的:尽管存在活动性脉管炎,但炎症指标(如 C 反应蛋白 (CRP) 和血沉)可能正常。血管损伤时,血管内皮细胞会分泌冯-威廉因子(vWF)。一些报告显示,脉管炎患者体内的 vWF 水平会升高。本研究旨在评估脉管炎患者血清中的 vWF 浓度,将其作为疾病活动性的一种可能的生物标志物,并对现有文献进行回顾:方法:对患有系统性血管炎的成人患者进行前瞻性登记。采用伯明翰血管炎活动性评分(BVAS)第 3 版记录疾病活动性。血型调整后的 vWF 抗原血清水平在诊断时进行评估,如果有的话,在治疗后进行评估:25名脉管炎患者与15名健康对照者进行了比较。患者的平均年龄为 56±17 岁,56% 为女性。40%的患者患有抗中性粒细胞胞浆自身抗体相关性血管炎,20%患有巨细胞动脉炎,16%患有结节性多动脉炎,8%患有高安动脉炎,其余患者患有其他血管炎。平均病程为 3.4 ± 4.8 年。活动性脉管炎患者的平均 vWF 高于健康对照组(212 ± 81% vs 106 ± 26%,P < 0.001)。有 13 名活动性脉管炎患者在接受治疗后病情得到缓解或疾病活动性较低,随访时 vWF 水平显著下降。在接受白细胞介素-6抑制剂治疗的五名患者中,有三名患者尽管CRP水平正常,但vWF却升高了,而此时脉管炎仍处于临床活动期。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.70
自引率
4.80%
发文量
90
审稿时长
6-12 weeks
期刊介绍: Scandinavian Journal of Rheumatology is the official journal of the Scandinavian Society for Rheumatology, a non-profit organization following the statutes of the Scandinavian Society for Rheumatology/Scandinavian Research Foundation. The main objective of the Foundation is to support research and promote information and knowledge about rheumatology and related fields. The annual surplus by running the Journal is awarded to young, talented, researchers within the field of rheumatology.pasting The Scandinavian Journal of Rheumatology is an international scientific journal covering clinical and experimental aspects of rheumatic diseases. The journal provides essential reading for rheumatologists as well as general practitioners, orthopaedic surgeons, radiologists, pharmacologists, pathologists and other health professionals with an interest in patients with rheumatic diseases. The journal publishes original articles as well as reviews, editorials, letters and supplements within the various fields of clinical and experimental rheumatology, including; Epidemiology Aetiology and pathogenesis Treatment and prophylaxis Laboratory aspects including genetics, biochemistry, immunology, immunopathology, microbiology, histopathology, pathophysiology and pharmacology Radiological aspects including X-ray, ultrasonography, CT, MRI and other forms of imaging.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信